✨
AI Summary
- Former FDA staffers discuss 2026 regulatory updates.
- Operation TrialBlazer's implications and nuances are explored.
- Insights on navigating biopharma's evolving compliance landscape.
Guests on This Episode
ET
Elizabeth Trentacost
1 podcast appearance
ET
Eva Temkin
1 podcast appearance